Utah Medical Products (NASDAQ:UTMD) CEO Kevin Cornwell Purchases 1,000 Shares of Stock

Utah Medical Products, Inc. (NASDAQ:UTMD) CEO Kevin Cornwell purchased 1,000 shares of the business’s stock in a transaction on Thursday, October 29th. The stock was purchased at an average cost of $66.75 per share, with a total value of $66,750.00. Following the acquisition, the chief executive officer owned 189,472 shares in the company, valued at approximately $12,647,256. This represents a 0.53% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Utah Medical Products Trading Down 3.0%

Shares of UTMD stock opened at $66.80 on Friday. The stock has a 50 day moving average of $72.97 and a two-hundred day moving average of $67.97. Utah Medical Products, Inc. has a 12 month low of $53.66 and a 12 month high of $76.89. The company has a market capitalization of $212.42 million, a P/E ratio of 20.00 and a beta of 0.38.

Utah Medical Products (NASDAQ:UTMD) last released its quarterly earnings data on Thursday, October 22nd. The medical instruments supplier reported $0.88 earnings per share (EPS) for the quarter. The business had revenue of $8.62 million for the quarter. Utah Medical Products had a return on equity of 8.83% and a net margin of 30.48%.

Utah Medical Products Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, October 5th. Shareholders of record on Thursday, September 17th were paid a dividend of $0.31 per share. The ex-dividend date was Thursday, September 17th. This represents a $1.24 dividend on an annualized basis and a yield of 1.9%. Utah Medical Products’s payout ratio is currently 37.13%.

Institutional Investors Weigh In On Utah Medical Products

Institutional investors and hedge funds have recently modified their holdings of the business. State of Wyoming raised its position in shares of Utah Medical Products by 39.1% during the 3rd quarter. State of Wyoming now owns 6,683 shares of the medical instruments supplier’s stock valued at $495,000 after acquiring an additional 1,880 shares during the last quarter. Cardinal Capital Management boosted its position in shares of Utah Medical Products by 8.7% in the 3rd quarter. Cardinal Capital Management now owns 29,458 shares of the medical instruments supplier’s stock worth $2,190,000 after purchasing an additional 2,364 shares during the last quarter. Empowered Funds LLC bought a new position in shares of Utah Medical Products in the 2nd quarter worth $225,000. Bank of America Corp DE bought a new position in shares of Utah Medical Products in the 2nd quarter worth $283,000. Finally, Sanctuary Advisors LLC acquired a new stake in shares of Utah Medical Products during the second quarter worth $544,000. 69.60% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Utah Medical Products from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, September 9th. One investment analyst has rated the stock with a Hold rating. According to data from MarketBeat, the company currently has an average rating of “Hold”.

Utah Medical Products Company Profile

Utah Medical Products, Inc (NASDAQ:UTMD) develops, manufactures and distributes medical devices used primarily in hospital and clinical settings. The company focuses on specialized products for women’s health, childbirth, neonatal care, electrosurgery, gastroenterology and related medical applications.

Its product portfolio includes fetal monitoring electrodes and catheters, intrauterine pressure monitoring devices, vacuum-assisted delivery systems, neonatal respiratory and care products, electrosurgical accessories, and other disposable and specialty medical instruments.